56013-01-5

Usage

Uses

Intermediate in the preparation of Retinoic Acid derivatives and Retinoid analogs.

Upstream product

• 472-20-8 β-cyclogeraniol 
• 6399-81-1 triphenylphosphine hydrobromide 
• 59633-88-4 2-(bromomethyl)-1,3,3-trimethylcyclohex-1-ene 
• 603-35-0 triphenylphosphine 
• 78-70-6 3,7-dimethylocta-1,6-dien-3-ol 
• 432-25-7 2,6,6-trimethylcyclohex-1-enecarbaldehyde 

Downstream Products

• 14398-44-8 (2Z,4E)-3-methyl-5-(2',6',6'-trimethylcyclohex-1'-en-1'-yl)-2,4-pentadienoic acid 
• 14538-58-0 3-methyl-5t-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2t,4-dienoic acid methyl ester 
• 75859-98-2 (2E,4E)-3-Bromo-5-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2,4-dienoic acid ethyl ester 
• 86471-17-2 methyl 6-<(Z)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethen-1-yl>-2-naphthalenecarboxylate 
• 86471-12-7 methyl 6-<(E)-2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethen-1-yl>-2-naphthalenecarboxylate 
• 77837-62-8 (1E,3E)-1-(4-carboethoxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 186953-27-5 (2E,4E)-tert-butyldiphenylsilyl 3-fluoro-5-(2,6,6-trimethylcyclohex-1-en-1-yl)penta-2,4-dien-1-yl ether 
• 165605-00-5 tert-Butyl-[(2E,4E,6E,8E)-3,6-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenyloxy]-dimethyl-silane 
• 219130-10-6 2-((1E,3E)-7,7-Dimethoxy-3-methyl-hepta-1,3-dienyl)-1,3,3-trimethyl-cyclohexene 
• 189271-84-9 2-[(E)-2-(2,6,6-Trimethyl-cyclohex-1-enyl)-vinyl]-furan-3-carboxylic acid ethyl ester 
• 223742-36-7 2-[(E)-2-(2,6,6-Trimethyl-cyclohex-1-enyl)-vinyl]-benzoic acid ethyl ester 
• 100991-97-7 ethyl (13E)-20,20,20-trifluororetinoate 
• 253681-52-6 (13Z)-13-bromo-13-desmethylretinyl tert-butyldiphenylsilyl ether 
• 454194-31-1 (2E,4E)-3-methyl-5-[2-[(E)-2-(2,6,6-trimethylcyclohex-1-en-1-yl)ethenyl]-1-cyclopenten-1-yl]-2,4-pentadien-1-ol 

Relevant academic research and scientific papers

Preparation method of vitamin A ester intermediate C15 and vitamin A ester

The invention provides a preparation method of a vitamin A ester intermediate C15 and vitamin A ester. The method comprises the following steps: carrying out a halogenation reaction and a cyclizationreaction on 3, 7-dimethyl-3-hydroxy-1, 6-octadiene as an initial raw material, carrying out a substitution reaction on the obtained product and triphenylphosphine or triester phosphite to prepare a corresponding Wittig reagent, carrying out a Wittig reaction on the Wittig reagent and 2-methyl-4-acetoxy-2-butenal, performing acidifying, hydrolyzing and acidifying the obtained product, and carryingout a substitution reaction on the hydrolyzed and acidified product and triphenylphosphine or triester phosphite to prepare C15. The vitamin A ester can be prepared by carrying out a Wittig reaction on the obtained C15 and 2-methyl-4-R3 substituent carbonyloxy-2-butenal. The method has the advantages of single reaction type, easy operation and realization of reaction conditions, safe and environment-friendly operation, simple post-treatment and low cost; and the reaction activity is strong, the reaction selectivity is high, the atom economy is high, and the target product yield and purity arehigh.

STABILIZED MUTANT OPSIN PROTEINS

Methods and compositions for stabilizing opsin protein, such as a Pro23His mutant opsin protein, in a vertebrate visual system, by administration of opsin-binding synthetic retinoids, are provided. The mutant opsin protein binds to the synthetic retinoid, which stabilizes the mutant opsin protein and/or ameliorates the effects of the mutant opsin protein on the vertebrate visual system.

STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Bacterial Carotenoids. 51. Chirality and Chiroptical Properties of (2S)-2-Isopentenyl-3,4-dehydrorhodopin (C.p. 482) and Related C45-Carotenoids

Dehydration of C.p. 482 (2-isopentenyl-3,4-dehydrorhodopin; 2-(3-methyl-2-butenyl)-3,4-didehydro-1,2-dihyro-ψ,ψ-caroten-1-ol) with POCl3 provided a tert chloride, a conjugated and a non-conjugated anhydro product in varying yields depending on reaction conditions.Chiroptical propeties of C.p. 482 and its trimethylsilyl ether were considered.The 2S-chrirality of C.p. 482 was demonstrated by chiroptical comparison of its non-conjugated anhydro derivative with the same (2S)-carotenoid, here prepared by total synthesis.The dehydration to the non-conjugated anhydro derivative only slightly modified the CD curve but reduced Δε values significantly.For futher chiroptical studies (2'S)-2'-(3-methyl-2-butenyl)-1',16',3',4'-tetradehydro-1',2'-dihydro-β,ψ-carotene was synthesized.The 2'-isopentenyl substituent had a similar influence on the Cotton effects of the monochiral monocyclic C45-, the monochiral aliphatic C45- and the homodichiral aliphatic C50-carotenes considered.